Newton Biocapital, established in 2017 and headquartered in Brussels, Belgium, is a venture capital firm specializing in early-stage investments in the biotech and life science sectors. The company focuses on Europe and Japan, supporting promising start-ups and undervalued late-stage projects in the prevention and treatment of chronic diseases. As a lead investor, Newton Biocapital provides not only capital but also expert guidance and coaching to bio-entrepreneurs throughout the development stages of their projects. The firm's investment approach aligns with ESG principles, seeking opportunities that meet the criteria under Article 8 of the SFDR.
Augustine Therapeutics N.V., founded in 2019 and based in Gent, Belgium, focuses on developing innovative medicines for patients suffering from Charcot-Marie-Tooth disease and other neuromuscular disorders. The company is engaged in two drug discovery programs aimed at identifying new generations of selective HDAC6 inhibitors, which are designed to address axonopathies, including Charcot-Marie-Tooth disease. These novel compounds are intended to protect against nerve degeneration and facilitate the repair of peripheral myelin and axons. By advancing these therapeutic drugs, Augustine Therapeutics aims to enhance the quality of life for patients affected by these debilitating conditions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.